https://www.openbell.ai/ 2026-11-02T13:45:45.116Z hourly 1.0 https://www.openbell.ai/support 2026-11-02T13:45:45.116Z monthly 0.7 https://www.openbell.ai/privacy 2026-11-02T13:45:45.116Z monthly 0.5 https://www.openbell.ai/terms 2026-11-02T13:45:45.116Z monthly 0.5 https://www.openbell.ai/feed.json 2026-11-02T13:45:45.116Z hourly 0.8 https://www.openbell.ai/news/WAWI:1793624603000 2026-11-02T13:03:23.000Z daily 0.9 https://cdn.brandfetch.io/WAWI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Wallenius Wilhelmsen Secures $700 Million Shipping Contract in Asia Wallenius Wilhelmsen finalized a shipping contract valued at $700 million in the Asian market, supporting its logistics and ocean freight operations. The report did not disclose the counterparty or contract duration, and provided no details on financial impact or stock movement. https://www.openbell.ai/news/BAVA:1793624545000 2026-11-02T13:02:25.000Z daily 0.9 https://cdn.brandfetch.io/BAVA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bavarian Nordic Secures Multi-Year Mpox and Smallpox Vaccine Contract with UK Government Bavarian Nordic secured a new multi-year contract with the UK government to supply mpox and smallpox vaccines. The agreement supports the company’s role in providing vaccines to public health agencies; the article does not disclose the contract’s financial value or report any stock-price impact. https://www.openbell.ai/news/LITE:1793624535000 2026-11-02T13:02:15.000Z daily 0.9 https://cdn.brandfetch.io/LITE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Lumentum Reports Fiscal First Quarter 2027 Financial Results Lumentum reported fiscal first-quarter 2027 revenue of $1.262 billion, up from $533.8 million a year earlier. GAAP earnings rose to $360.3 million, or $3.54 per share, from $4.2 million, or $0.05 per share; adjusted earnings were $461.1 million, or $4.57 per share. The company cited strong performance across its segments, particularly pump lasers and optical circuit switches, and announced a second major NPO/CPO win backed by purchase commitments exceeding $5 billion. https://www.openbell.ai/news/8053:1793624515000 2026-11-02T13:01:55.000Z daily 0.9 https://cdn.brandfetch.io/8053/w/400/h/400?c=1idopYfmtR7ZKg8QMud Sumitomo Corporation Reports H1 Profit Growth and Raises FY2026 Guidance Sumitomo Corporation reported first-half profit of ¥347.9 billion and underlying profit of ¥334.0 billion. The company raised its fiscal 2026 full-year profit forecast to ¥670.0 billion, including a ¥30.0 billion loss buffer, and increased its annual dividend forecast to ¥44 per share. https://www.openbell.ai/news/CHH:1793622797000 2026-11-02T12:33:17.000Z daily 0.9 https://cdn.brandfetch.io/CHH/w/400/h/400?c=1idopYfmtR7ZKg8QMud Choice Hotels International Reports Q3 2026 Financial Results Choice Hotels International reported Q3 2026 revenue of $458.3 million, above analyst estimates of about $448 million, and adjusted EPS of $2.33, exceeding the $2.29 consensus. RevPAR rose 11.7% year over year, and the company said it continued to advance its asset-light strategy. Choice narrowed its full-year adjusted EPS guidance to $6.92–$7.07 and projected adjusted EBITDA of $646 million at the midpoint. https://www.openbell.ai/news/FCR.UN:1793622788000 2026-11-02T12:33:08.000Z daily 0.9 https://cdn.brandfetch.io/FCR.UN/w/400/h/400?c=1idopYfmtR7ZKg8QMud First Capital REIT Announces Strategic Arrangement Agreement First Capital REIT’s Board and Special Committee concluded, following a strategic review, that an arrangement agreement offering cash consideration to unitholders provides compelling value. Trustees and the Manager signed support and voting agreements covering approximately 5.9% of the units. The transaction remains subject to customary closing conditions and required approvals, with completion expected in the first quarter of 2027. https://www.openbell.ai/news/GEO:1793622760000 2026-11-02T12:32:40.000Z daily 0.9 https://cdn.brandfetch.io/GEO/w/400/h/400?c=1idopYfmtR7ZKg8QMud The GEO Group Announces 10-Year ICE Agreement for Texas Complex The GEO Group announced a 10-year agreement with U.S. Immigration and Customs Enforcement for a facility complex in Texas. The deal extends the company’s role in operating government detention and processing facilities; the article did not report financial terms or a stock-price impact. https://www.openbell.ai/news/CIFR:1793622758000 2026-11-02T12:32:38.000Z daily 0.9 https://cdn.brandfetch.io/CIFR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cipher Digital Reports Third Quarter 2026 Financial Results and Business Update Cipher Digital reported its third-quarter 2026 results and recognized its first high-performance computing lease revenue at the Black Pearl site. It extended the Barber Lake lease to 20 years, bringing contracted revenue there to approximately $9.1 billion. The company also received conditional base-load classification for 1 GW at Colchis, began developing natural-gas pipelines to support up to 2.5 GW of on-site generation, and acquired Horizon, a 70 MW Texas site expected to energize in 2029. The update reflects Cipher’s shift toward HPC and AI infrastructure; the article did not provide overall revenue, profit, or stock-price figures. https://www.openbell.ai/news/LXP:1793622756000 2026-11-02T12:32:36.000Z daily 0.9 https://cdn.brandfetch.io/LXP/w/400/h/400?c=1idopYfmtR7ZKg8QMud Brookfield Asset Management and CPP Investments Complete Acquisition of LXP Industrial Trust Brookfield Asset Management and CPP Investments completed their all-cash acquisition of LXP Industrial Trust, in a transaction valued at approximately $5.2 billion, including net debt and preferred equity. LXP shareholders received $61.20 per share in cash. LXP has ceased trading on the New York Stock Exchange and is now privately held. https://www.openbell.ai/news/AXSM:1793622755000 2026-11-02T12:32:35.000Z daily 0.9 https://cdn.brandfetch.io/AXSM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Axsome Therapeutics Reports Third Quarter 2026 Financial Results Axsome Therapeutics reported third-quarter 2026 revenue of $259.7 million, up 52% year over year and above the FactSet consensus estimate of $249.2 million. Its loss was $0.25 per share, narrower than the expected loss of $0.63. Management said the company has exceeded a $1 billion annual revenue run rate and expects continued momentum from demand for its central nervous system therapies.